Asset Details
Do you wish to reserve the book?
Combining treatments for migraine prophylaxis: the state-of-the-art
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Combining treatments for migraine prophylaxis: the state-of-the-art
Do you wish to request the book?
Combining treatments for migraine prophylaxis: the state-of-the-art
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Combining treatments for migraine prophylaxis: the state-of-the-art
2024
Overview
Combination treatments for migraine prophylaxis present a promising approach to addressing the diverse and complex mechanisms underlying migraine. This review explores the potential of combining oral conventional prophylactics, onabotulinumtoxin A, monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway, and small molecule CGRP receptor antagonists (gepants). Among the most promising strategies, dual CGRP inhibition through mAbs and gepants may enhance efficacy by targeting both the CGRP peptide and its receptor, while the combination of onabotulinumtoxin A with CGRP treatments offers synergistic pain relief. Oral non-CGRP treatments, which are accessible and often prescribed for patients with comorbid conditions, provide an affordable and practical option in combination regimens. Despite the potential of these combinations, there is a lack of evidence to support their widespread inclusion in clinical guidelines. The high cost of certain combinations, such as onabotulinumtoxin A with a CGRP mAb or dual anti-CGRP mAbs, presents feasibility challenges. Further large-scale trials are needed to establish safe and effective combination protocols and solidify their role in clinical practice, particularly for treatment-resistant patients.
Graphical Abstract
Publisher
Springer Milan,Springer Nature B.V,BMC
Subject
Antibodies, Monoclonal - therapeutic use
/ Botulinum Toxins, Type A - administration & dosage
/ Botulinum Toxins, Type A - therapeutic use
/ Calcitonin gene-related peptide
/ Calcitonin Gene-Related Peptide - antagonists & inhibitors
/ Calcitonin Gene-Related Peptide - immunology
/ Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use
/ CGRP
/ Gepants
/ Headache
/ Humans
/ Medicine
/ Migraine
/ Migraine Disorders - drug therapy
/ Migraine Disorders - prevention & control
/ Patients
/ Peptides
/ Review
